MedTech Holiday Social

December 13, 2017 — Vancouver, BC

Come and meet your peers in Metro Vancouver’s medical technology industry and join LifeSciences BC community for a festive evening of networking and socializing. Your ticket includes a burger and a choice of one: beer, glass of house red or white wine or a well highball drink.

Upcoming Events

36th Annual J.P. Morgan Healthcare Conference 2018

January 8-11, 2018 — San Francisco, CA

The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

In 2018, J.P. Morgan expects more than 400 companies, both public and private, to deliver presentations to more than 8,000 attendees. The conference provides a unique opportunity for investors to visit with so many inter-related industry leaders in one setting.

RESI San Francisco 2018

January 9, 2018 — San Francisco, CA

The Redefining Early Stage Investments (RESI) Conference is an ongoing conference series that will be establishing a global circuit for early stage life sciences companies to source investors, create relationships, and eventually, get funding. The RESI conference focuses on the diverse breadth of early stage investors that LSN tracks, including Family Offices, Venture Philanthropy Funds, VCs, Angel Groups, Corporate Venture Capital Funds, and more.

To understand the challenges and explore a variety of solutions to move life sciences innovation forward.Hear about the need to engage in innovation and how it will affect your organization by leveraging talent and technology across the country.Meet with the different stakeholders, and learn the many ways to engage with Canada’s wide innovation ecosystem.

Blakes Breakfast Speaking Event on the Emerging Cannabis Industry

December 7, 2017 — Vancouver, BC

LifeSciences BC have brought together a panel of industry experts to discuss the issues affecting the emerging cannabis industry. The panel members will address public and private finance for cannabis companies and regulatory matters affecting the industry.

RESI New York City 2017

November 15, 2017 — New York City, NY

The Redefining Early Stage Investments (RESI) Conference is an ongoing conference series that will be establishing a global circuit for early stage life sciences companies to source investors, create relationships, and eventually, get funding. The RESI conference focuses on the diverse breadth of early stage investors that LSN tracks, including Family Offices, Venture Philanthropy Funds, VCs, Angel Groups, Corporate Venture Capital Funds, and more.

Medica 2017: World Forum for Medicine

November 13-16, 2017 — Düsseldorf, Germany

MEDICA is the world’s largest event for the medical sector. For more than 40 years it has been firmly established on every expert’s calendar. There are many reasons why MEDICA is so unique. Firstly, the event is the largest medical trade fair in the world – in 2016 it attracted more than 5,100 exhibitors from 70 countries in 17 halls.

LifeSciences BC McCarthy Spotlight Speaking Series

November 9, 2017 — Vancouver, BC

Event topic: Beyond the Science, Who is Your Market?

The McCarthy Spotlight Speaking Series is one of LifeSciences BC’s longest-standing event series. Held twice a year, these events start with presentations on specific topics by local representatives of LifeSciences BC members. Typically, the event is attended by a cross-section of approximately 40 of our life sciences community members representing mainly industry, NPOs, and Government.

In the past, the series has featured topics focusing on attracting and keeping good talent, technology and licensing, M&A and Capital Markets, to name a few.

BioTech Pharma Summit 2017: Companion Diagnostics & Biomarkers

October 26-27, 2017 — Porto, Portugal

Ali Ardakani, Managing Director at Novateur Ventures, spoke at the BioTech Pharma Summit 2017 about the best practices of companion diagnostics for better drug development and successful reimbursement. In his presentation he looked at several best and worst cases of challenges of developing companion diagnostics and how the fait of both the drug and diagnostics changed based the clinical outcome.

Invest in BC 2017 (LifeSciences BC)

October 18, 2017 — Vancouver, BC

INVEST IN BC 2017 brings together stakeholders in the healthcare innovation ecosystem for an exciting day of company pitches. Entrepreneurs tell their stories, get feedback and engagement from a wide range of investor stakeholders including; angel investors, venture capital firms, corporate ventures and funding foundations.

2017 Interface Health Summit

October 16-17, 2017 — Vancouver, BC

The 2017 Interface Health Summit presents two full days of being engaged, informed, inspired and connected to digital health innovators. Enjoy amazing talks, take part in reverse startup pitches and educational sessions, meet investors from Canada, Silicon Valley, and China – investors who manage hundreds of millions in innovation funds! Watch the Top 10 Grand Finale of #IHCX2017 and Awards Show live.

Vancouver Regional Forum

October 12, 2017 — Vancouver, BC

The CVF Vancouver Regional Forum hosted by VANTEC Angel Network is a half-day event packed with engaging company presentations by BC’s top fundraising health innovators who are pre-screened, validated, and investor-worthy. In addition, there will be informative panel discussions about investing in Health Innovation by thought leaders in the ecosystem.

Ali Ardakani, Managing Director of Novateur Ventures was a panelist at the Cascadia Venture Forum – Vancouver Regional Forum. The Panel Topic was Building Value and Preparing for an Exit – What Exit Partners Are Looking.

Meet Industry Leaders: Roche Venture Fund

September 27, 2017 — Vancouver, BC

A unique opportunity to hear from Karl Handelsman, Investment Director of Roche Venture Fund on lessons learned from a venture capitalist investing in early stage pre-clinical therapeutic companies. Their mission: “The Roche Venture Fund invests to develop commercially successful innovative life science companies.” The fund is a CHF 500 million evergreen fund that invests in life science companies in both pharmaceuticals and diagnostics with a focus on financial returns. Their offices are located in Basel, Switzerland and San Francisco.

His speech topic was “Winning Strategies for Biotech Startups”. He discussed the strategies companies deploy to cross the “Valley of Death” to build value. He also covered some of the destructive myths about biotech and venture.

Karl Handelsman has been a biotech venture investor for 18 years, prior to that he worked in business development at two biotech startups that were each acquired for billions.

BIO International Convention 2017

June 19-22, 2017 — San Diego, CA

The BIO International Convention attracts over 15,000 biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. This event covers a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.

Novateur sponsored the BIOTECanada’s Coast to Coast Competition in the BIO 2017 Canadian Pavilion.

Gallery

Redefining Early Stage Investments (RESI) Conference

June 19, 2017 — San Diego, CA

The Redefining Early Stage Investments (RESI) Conference is an ongoing conference series that will be establishing a global circuit for early stage life sciences companies to source investors, create relationships, and eventually, get funding. The RESI conference focuses on the diverse breadth of early stage investors that LSN tracks, including Family Offices, Venture Philanthropy Funds, VCs, Angel Groups, Corporate Venture Capital Funds, and more.

19th Annual LifeSciences BC Awards

April 19, 2017 — Vancouver, BC

LifeSciences BC’s 19th Annual LifeSciences BC Awards is an opportunity to celebrate our community’s many achievements, small wins and big victories, with our peers, family and friends. This is our moment to recognize and honour the efforts of all those who have invested their lives’ work in mastering successful health outcomes.

B.C. has found its place on the international life sciences stage and is recognized in Canada and beyond for its significant accomplishments in medical technology, biopharmaceuticals, health delivery systems, and medical research & development initiatives – the envy of many. We have reached beyond our borders to impact patient health and connect to the world at large, while ensuring the life science sector here, at home, remains vibrant and sustainable.

2017 theme, Translating Insights into Action, will consider the companies, organizations, individuals and institutions that have successfully taken ideas and brought those innovations to life. Successfully aligning and implementing the many research functions and corporate components that disrupt the usual and well-worn, by creating, developing or advancing new therapeutic solutions in clinical and translational medical science.

Medical Device Commercialization Playbook 2017 Vancouver

A full day of industry speakers and panels from British Columbia and across North America will discuss what it takes to Get Your Product Right. Network and learn 2017 trends, opportunities, and strategies for: Entrepreneur Case Studies, Getting the Product Right, and Clinical/Regulatory advice from industry veterans.

Spend a day at the Vancouver Convention Centre sharing expertise, learning, and collaborating to foster innovation.

Novateur team attended this event and Ali Ardakani, the Managing Director of Novateur delivered a speech on “Nitric Oxide – A Comeback Story“.

Redefining Early Stage Investments (RESI) Conference

April 4, 2017 — Toronto, ON

The Redefining Early Stage Investments (RESI) Conference is an ongoing conference series that will be establishing a global circuit for early stage life sciences companies to source investors, create relationships, and eventually, get funding. The RESI conference focuses on the diverse breadth of early stage investors that LSN tracks, including Family Offices, Venture Philanthropy Funds, VCs, Angel Groups, Corporate Venture Capital Funds, and more.

Medical Device Commercialization Playbook 2017 Toronto

March 30, 2017 — Toronto, ON

Medical Device Commercialization Playbook 2017, Canada’s premiere innovation and commercialization event for medical device professionals, is coming to the MaRS Discovery District on March 30, 2017. A full day of industry speakers and panels from across North America discuss what it takes to Get The Product Right.

#BCTECH Summit 2017

March 14-15, 2017 — Vancouver, BC

The #BCTECH Summit is the largest technology conference in British Columbia showcasing the province’s vibrant technology industry. Attend, build cross-sector opportunities for your business and explore the latest ideas and innovations fueling our economy today. From innovations in eHealth data, autonomous vehicles and customer experience, to emerging ideas in cleantech, agritech and aerospace, the two-day event will give you the information and tools you need to move forward in a world where technology is impacting every part of our economy – and our lives. The #BCTECH Summit brings together tech entrepreneurs, anchor companies, business leaders from traditional industries, investors, government and academia to establish new connections, nurture existing networks, and exchange fresh ideas around innovation driving business growth.

35th Annual J. P. Morgan Healthcare Conference

January 9-12, 2017 — San Francisco, CA

The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

At the Westin St. Francis in San Francisco, the annual J.P. Morgan Healthcare Conference brings thousands of investors from around the world together. The hundreds of companies presenting run the gamut, from start-ups to those with more than $300 billion in market cap, and encompass the entire global healthcare landscape, including pharmaceutical firms, healthcare service providers, profit and not-for-profits, and medical device companies.

Redefining Early Stage Investments (RESI) Conference

January 10, 2017 — San Francisco, CA

The Redefining Early Stage Investments (RESI) Conference is an ongoing conference series that will be establishing a global circuit for early stage life sciences companies to source investors, create relationships, and eventually, get funding. The RESI conference focuses on the diverse breadth of early stage investors that LSN tracks, including Family Offices, Venture Philanthropy Funds, VCs, Angel Groups, Corporate Venture Capital Funds, and more.

Past Events - 2016

McCarthy Spotlight Speaking Series on “Exporting to the US and trends at the FDA”

November 17, 2016 — Vancouver, BC

LifeSciences BC is pleased to feature Novateur Ventures Inc. and LivaNova Canada Corp. at the McCarthy Spotlight Speaking Event on “Exporting to the U.S. and interesting trends to be aware of at the FDA”.

Event topics:

Interesting and current trends to be aware of at the FDA

Exporting to the US from a medical device perspectives

How the US Election outcomes might impact on how the FDA makes decisions

Featured Speakers and Presentations

Thomas W Stephens, PhD

Head Regulatory Affairs, Novateur Ventures

Full bio

Dr. Thomas Stephens has more than 25 years of experience in pharmaceutical development and he contributed to multiple INDs and CTAs in the USA, Europe, Australia, South Africa, India and Mexico. Dr. Stephens has several years of experience in Lilly global regulatory affairs as Chief Operating Officer and Senior Regulatory Scientist within USA regulatory affairs in therapeutic areas of diabetes, obesity and endocrine therapeutics, including pulmonary insulin, growth hormone, basal insulin, leptin and beta3 adrenergic receptor agonist. Dr. Stephens previously worked as Clinical Research Advisor / Asset Manager and Chief Regulatory Officer of the Chorus Division and he has managed seventeen Phase I-II development programs in a range of therapeutic areas (migraine treatment and prevention, chronic pain, depression, cognition, anti-thrombotics, postmenopausal symptoms, type 2 diabetes, osteoporosis, osteoarthritis, rheumatoid arthritis, transplant rejection and obesity). Dr. Stephens was responsible for developing initial global regulatory capability through contract resources and development of a global internet-based network for coordinating development. The Chorus Group is an autonomous division of Eli Lilly and Company; Dr. Stephens with two other founders developed business processes, defined and developed roles and SOPs for Chorus. Dr. Stephens also spent several years in pre-clinical through Phase II project management (therapeutic areas including cancer, cognition, antiviral, anti-thrombotic, lupus, rheumatoid arthritis, and sepsis) in the LRL Project Management group. He has also led discovery research programs in diabetes and obesity therapeutics including research on leptin, thiazolidinediones and amylin. Prior to work in drug and device development, Dr. Stephens was a supervisor of research and quality assurance for an in-vitro diagnostics company as well as general manager for another. Dr. Stephens received his PhD degree in Biochemistry with minor in Biomathematics from Indiana University School of Medicine and he has RAC (US) professional certification.

Carol H Stephens, PhD

Drug and Diagnostic Development Lead, Novateur Ventures

Full bio

Dr. Carol Stephens has 28 years of experience in drug development and support with focus on regulatory planning, negotiation, execution, and compliance. She has worked on 6 successful new NDAs and BLAs and 4 supplements for new indications as well as INDs. Dr. Stephens worked for 25 years at Eli Lilly and Company where she focused on CNS, cardiovascular, endocrine, and oncology drugs, in vitro diagnostics, and drug-device combinations. In Regulatory Affairs at Lilly, she supported products from early clinical phases through submission, approval and market growth. Her experience includes regulatory strategies for obtaining product approvals and negotiations with regulatory authorities backed up by her expertise in US and international regulations, guidances, and agency precedents. Dr. Stephens has broad experience in using desired physician’s prescribing label claims as driver of the development process. In addition to roles within Regulatory Affairs, Dr. Stephens has served as a manager of clinical trials, alliance manager of partnerships with US and international biotechs, and project manager of drug and device development. Dr. Stephens received her PhD in Communications from the University of Wisconsin, and she has a number of publications in the pharmaceutical industry.

Gallery

2016 Access to Innovation Conference

November 2-3, 2016 — Vancouver, BC

LifeSciences BC’s Access to Innovation Conference brings together academia, health institutions, government and industry to engage in discussions on how we can improve on access to innovation. Attracting over 300+ participants last year from B.C., Canada and internationally.

This focus of the two days are:

Day 1 – R&D Perspective: How to accelerate translational research to company development and marketed products & services;
Day 2 – Health System Perspective: Models of innovation uptake into healthcare systems and how to accelerate Market Enablers.

Cascadia Venture Forum 2016

We are proud to announce that Novateur is a gold sponsor of the Cascadia Venture Forum 2016.

Vancouver Forum: October 4, 2016 at NACO Summit

Portland Forum: October 20-21, 2016 at Oregon Bio Annual Conference

Seattle CVF Summit: October 27, 2016 at Cambia Grove

The Cascadia Venture Forum is poised to become the Pacific Northwest’s premier seed financing investment forum for life science start-ups. It is a key driver in the establishment of a thriving life sciences innovation cluster that spans the entire Pacific Northwest including British Columbia,Washington and Oregon.

Angel investors, venture capitalists, industry players and other innovation ecosystem members are invited to attend a half-day session of fast-pitches and in-depth investment presentations by pre-screened, validated and investor-ready companies.

The BIO Investor Forum 2016

October 18-19, 2016 — San Francisco, CA

The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One PartneringTM meetings.

INTERFACE Health Summit 2016

We invite you to come to Vancouver – one of the world’s most creative and healthiest cities – and the Vancouver Convention Centre – a spectacular feat of green architecture right on the Pacific Ocean, next to Stanley Park and across from the North Shore mountains. Come to meet some remarkable people, share your ideas and discuss THE FUTURE OF HEALTH!

The INTERFACE Health Summit 2016 is the fifth annual global conference. It is a two-day event created to engage, inform, inspire and connect digital health innovators and other health stakeholders from Canada and around the world.

5th annual TVM Capital Life Science Autumn Conference 2016

September 19, 2016 — Montréal, Québec

The annual invitation only conference is attended by more than 200 international participants from Asia, the United States and Europe who join us to network with senior decision makers from biotech and pharmaceutical companies as well as Venture Capital and investor groups.

Redefining Early Stage Investments (RESI) Conference

September 13, 2016 — Boston, MA

Redefining Early Stage Investments is an ongoing conference series establishing a global circuit for early stage life science companies, active investors, and various service providers to meet, create dialogues and start relationships – ultimately moving science and technology forward.

The RESI Conference series brings together fundraising CEOs and early-stage investors from around the globe, providing the opportunity for dialogue and relationship building, with the goal of eventual capital allocations.

Redefining Early Stage Investments (RESI) Conference

June 23, 2016 — Toronto, ON

MaRS Discovery District (MaRS) is collaborating with Life Science Nation (LSN) and Johnson & Johnson Innovation, JLABS (JLABS) to bring the Redefining Early Stage Investments (RESI) Conference to Toronto on June 23, 2016.

The RESI Conference series brings together fundraising CEOs and early-stage investors from around the globe, providing the opportunity for dialogue and relationship building, with the goal of eventual capital allocations.

20th Annual Novateur Salmon Barbeque

June 16, 2016 — University of British Columbia, Vancouver, BC

With a long and strong 20 year history, the Annual Novateur Salmon Barbeque offers the life sciences community the opportunity to enjoy a great meal in the company of 100+ peers in a breathtaking setting. Held each June at the scenic Cecil Green Park House.

BIO International Convention 2016

June 6-9, 2016 — San Francisco, CA

The BIO International Convention attracts 15,000+ biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. The 160,000+ square foot exhibition features more than 1,800 exhibitors including 55 state, regional and international pavilions and 8 specialized product focus zones.

ASCO Annual Meeting 2016

The Annual Meeting brings together 30,000 oncology professionals from around the world. Educational sessions feature world-renowned faculty discussing state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. Science sessions present the latest ground-breaking research in oral and poster format.

Collective Wisdom: The Future of Patient-Centered Care and Research

“The theme for ASCO 2016 is Collective Wisdom: The Future of Patient-Centered Care and Research. Spanning disciplines, disease sites, and treatment approaches, it is our combined knowledge that will shape the future of patient care and research. We must partner with health care professionals and specialists of diverse backgrounds to meet the evolving challenges in providing optimal care to our patients. With exciting advances in big data technology, our collective wisdom will become all the more powerful as new insights will be revealed in seconds, not years. The impact of our wisdom, however, can only be as great as our ability to strengthen the delivery of and access to high-quality cancer care. As medical professionals and as a Society, we must all continue to evolve cancer care and research with each new discovery. Fifty years from now, we can hope that future medical professionals can look back and thank us for pioneering aspects of cancer treatment that were developed in our era.”

Invest in BC 2016

May 12, 2016 — Vancouver, BC

Innovative healthcare companies are a core element of the life sciences ecosystem and together with academia, health delivery institutions, clinicians and governments, these companies are fundamental to the growing bio-economy. This event will bring together a best-in-class, innovation centric, emerging and growth oriented life science companies from B.C.. The goal is to showcase the outstanding innovation, science, products and services that these companies offer; shared through their entrepreneurial leadership. These growing companies are not only about creating value, they are dedicated to having a compelling impact on patients.

2016 Bloom Burton & Co. Healthcare Investor Conference

May 2-3, 2016 — Toronto, ON

Bloom Burton is hosting its fourth annual Healthcare Investor Conference on May 2 and 3, 2016, at the Sheraton Centre Toronto Hotel, Toronto, Canada. We will host approximately 60 of Canada’s premier publicly-traded and venture-backed private companies together with the most promising pre-venture companies in the healthcare industry. The event will attract Canadian, U.S. and International investors who are interested in the latest developments in Canadian healthcare companies. Investors will have the opportunity to obtain corporate updates from presenting companies, and participate in our 1-on-1 meeting system with company management.

18th Annual LifeSciences BC Awards

April 21, 2016 — Vancouver, BC

LifeSciences BC’s 18th Annual LifeSciences BC Awards is an opportunity for the life sciences community to celebrate our work together. Recognizing the value creation continuum of the life sciences sector, we celebrate and honour those in our B.C. community who successfully position our province as a competitive global cluster.

B.C. has found its place on the international life sciences stage and is recognized in Canada and beyond for its significant accomplishments in medical technology, biopharmaceuticals, health delivery systems, and medical research & development initiatives – the envy of many. We have reached beyond our borders to impact patient health and connect to the world at large, while ensuring the life sciences sector here at home remains vibrant and sustainable.

This year’s theme, Local Catalyst – Global Connectivity, reflects those in our community who impact the local ecosystem so that B.C. can connect with the global life sciences community.

Medical Device Commercialization Playbook 2016

March 31, 2016 — Vancouver, BC

Medical Device Commercialization Playbook 2016: A full day of industry speakers and panels from across North America will discuss what it takes to Go from start-up to the first $50M. Network and learn 2016 trends and opportunities for scaling, regulatory issues, entrepreneurial strategy, and innovation design control from industry veterans.

Several Novateur team members attended the Medical Device Commercialization Playbook 2016.

28th Annual ROTH Conference

March 13-16, 2016 — Dana Point, CA

ROTH Capital Partners invites you to the 28th Annual Conference. This conference is one of the largest of its kind in the U.S. Following the success of previous year’s events, the ROTH Conference, with close to 550 participating companies and over 4,000 attendees, will feature presentations from public and private companies in a variety of sectors.

This gathering of institutional investors, private equity investors, VCs, company executives and service providers has become a must attend event for anyone working in the small and mid-cap space.

Several Novateur team members attended the 28th Annual ROTH Conference.

12th Annual BIOTECanada Investor Summit

February 26-28, 2016 — Whistler, BC

The BIOTECanada Investor Summit presents a unique and timely opportunity for investors, commercial partners and pre-commercial companies to connect, network and explore investment/partnership opportunities within the Canadian biotech industry. Each year ten emerging companies in search of investment capital are provided the opportunity to present their company and therapy to the investors and pharma partners.

Novateur proudly sponsored the reception of the BIOTECanada Investor Summit at the Whistler Sliding Centre.

#BCTECH Summit 2016

January 18-19, 2016 — Vancouver, BC

The #BCTECH Summit is a two-day event that will showcase BC’s vibrant technology industry, build cross-sector opportunities for businesses and explore the latest ideas that will drive a competitive advantage for British Columbia.

Novateur was exhibiting at the #BCTECHSummit 2016 as a part of the LifeSciences BC pavilion.

Biotech Showcase™ 2016

January 11-13, 2016 — San Francisco, CA

Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences.

Novateur team attended the Biotech Showcase™ 2016 company presentations and workshops, as well as participated in one-on-one networking sessions with numerous biotech companies.

Happy Holidays Everyone!

We founded Novateur this year with one mission: to provide virtual, world class solutions to biotech, med-tech, and pharmaceutical companies for the purposes of advancing their product development smarter and faster while spending less.

Access to Innovation: Healthcare Innovation in Life Sciences in BC

October 14 -15, 2015 — Vancouver, BC

Access to Innovation is bringing together health and life sciences stakeholders to present, discuss and deliver meaningful ways to improve collaboration, develop and deliver innovation, while improving outcomes and saving cost.

Agendas:

Winner of the iPad mini giveaway

Irina Chan is a 4th year student of Microbiology and Immunology at the University of British Columbia in Vancouver and she is interning for the Centre for Drug Research and Development (CDRD) at the division of Biologics. She attended the 19th Annual LifeSciences BC Salmon BBQ presented by Novateur and entered our giveaway. Irina is the lucky winner of an iPad mini and received her prize from Ali Ardakani, the Managing Director of Novateur.

19th Annual LifeSciences BC Salmon BBQ Presented by Novateur

June 11, 2015 — University of British Columbia, Vancouver, BC

Held each June at the scenic Cecil Green House, LifeSciences British Columbia’s Annual Salmon Barbeque has become one of most popular events of the year. It offers members of life sciences community the chance to come out and enjoy a great meal in the company of peers in a breathtaking setting – and without the formality of a sit-down banquet. It’s a great chance for the community to come together for some networking in a relaxed environment.

News & Updates

Survival: A Medical Memoir

From Drug Discovery To Clinical Cancer Trials

“This is the amazing true story of medical research, far outside the box, that led to the discovery of a novel antihistamine (DPPE) that helped chemotherapy drugs cure laboratory mice of cancer while protecting the bone marrow. The book chronicles an inventor’s passion to move DPPE from the laboratory to the clinic; the unprecedented facilitation of its development and approval for human use by university and government bureaucrats; the decision of a U.S. pharmaceutical giant that stopped DPPE in its tracks after it was declared inactive at an early time-point in a major breast cancer trial, only to show a marked survival advantage in a follow-up analysis 18 months later; and its dramatic rescue by a small Canadian biotech company that, with a combination of luck, venture capital and the FDA’s blessing, took it back into a final trial needed for its approval. Intertwined with the human drama are the politics and science behind the story, including an unanticipated research finding with implications that shook the public, drug companies and regulatory agencies.”